MedTrace Logo

Blood Transfusion in Patients With Lung Cancer

NCT05590429 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-10-21

No results posted yet for this study

Summary

The main purpose of approaching the anemic patient is to provide and maintain hemoglobin levels that will allow oxygen to reach the tissue at an adequate level. This critical level may vary from patient to patient, the age of the patient and other accompanying diseases are among the determining factors. The most important factor in transfusion indication is the insufficiency of cardiopulmonary compensation mechanisms due to anemia in the patient and the patient becoming symptomatic. Red blood cell (RBC) transfusions are common in the treatment of cancer patients.

In cancer patients, similar to other patient populations, the indication for RBC transfusion is to alleviate anemia, which is actually symptomatic. However, the decision to transfuse should not be guided solely by the hemoglobin concentration.

With this study, it is aimed to develop clinical practices to prevent unnecessary transfusion practices in lung cancer patients, to encourage the application of other supportive treatment options, and to take preventive measures before anemia develops

Conditions

  • Transfusion-Transmitted Infection

Interventions

OTHER

Blood transfusion

No intervention

Sponsors & Collaborators

  • Karadeniz Technical University

    lead OTHER

Principal Investigators

  • Mehtap Küçük, MD · Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University

  • A. Oguzhan Küçük, MD · Department of Chest Diseases, Division Of Intensive Care Medicine, Faculty of Medicine, Karadeniz Technical University

  • Merve Algın, MD · Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  • Ayşegul Pehlivanlar, MD · Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  • Funda Öztuna, Prof · Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

  • Olcay Ayçiçek · Department of Chest Diseases, Faculty of Medicine, Karadeniz Technical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2022-11-02
Completion
2022-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590429 on ClinicalTrials.gov